Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Trial Details

NCT ID

NCT06343077

Phase

PHASE2

Sponsor

Ashutosh Kumar Tewari

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Poly-ICLC intramuscular (IM) injection
• Poly-ICLC, Intertumoral (IT) injection

Locations (sample)

• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Written informed consent and HIPAA authorization for release of personal health information.
• NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age \> 18 years at the time of consent.
• ECOG Performance Status of 0-1 within 14 days prior to being registered for protocol therapy (Study Procedure Manual).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.